United States: Capitol Hill Healthcare Update - December 6, 2016

House Oks "Cures," Senate Votes This Week

The Senate this week is likely to give final congressional approval to legislation that adds billions of dollars for biomedical research and aims to speed the discovery and development of new drugs and medical devices. The "21st Century Cures" legislation won House approval last week 392-26. Although several Senate Democrats oppose the bill, the White House said it "strongly supports" its passage.

The bill authorizes $4.8 billion to NIH and $500 million to the FDA over 10 years, and states could apply for $1 billion in federal grants over two years to address opioid abuse. Congress would have to approve the funding each year. It also includes a series of provisions designed to accelerate the approval of new medical treatments. The legislation creates a new breakthrough approval pathway for medical devices but doesn't include any new exclusivities for drug makers.

Some Democrats, like Sens. Elizabeth Warren (D-MA) and Bernie Sanders (I-VT), have sharply criticized the bill as a "giveaway" to drug companies because it didn't include provisions addressing drug prices. "I know the difference between compromise and extortion," Warren said last week. Still, with the overwhelming House vote and President Obama's approval, the bill is expected to pass the Senate this week before Congress adjourns for the year.

GOP Will Repeal ACA, But Slowly

During the campaign, Donald Trump called the Affordable Care Act a "complete disaster" and vowed to repeal it as soon as he became president. Congress in early January will begin the process of unwinding Obamacare, but it will be several years before the law is wiped from federal statutes – if ever. Republicans are planning by late January or early February to approve fast-track legislation that would repeal most of President Obama's signature legislative achievement. Republicans will use a procedural budget maneuver called "reconciliation," which will allow them to bypass a Democratic-led filibuster in the Senate and approve the bill with only GOP votes.

That will be a powerful political moment for Republicans and for voters who backed Trump's call to repeal the law. But for the 20 million Americans who have insurance through Obamacare, not much will change. That's because Republicans are devising a long runway to transition to Trumpcare. The GOP will need that time because there isn't unanimity within the party over what comes next. Some Republicans want ACA 2.0 to include popular Obamacare provisions, like barring insurers from denying coverage based on pre-existing conditions, but exclude others, like mandates and provider taxes.

Despite the GOP's rhetoric on repealing Obamacare, the ACA will stay on the books at least through 2018 – and maybe longer. The real legislative action will not be on repeal but on devising what comes next, sparking both partisan clashes and what could be prolonged Republican arguments among themselves.

Walden Wins Key Healthcare Gavel

Rep. Greg Walden (R-OR) won support of House Republican leaders last week and was elected the next chairman of the House Energy and Commerce Committee. The committee has wide jurisdiction over healthcare regulatory policy, including at the FDA, NIH and CDC. The panel also oversees Medicare Part D. It will be the lead House committee next year reviewing the FDA's user fee agreements with medical device, pharmaceutical, biologic and generics manufacturers. Walden, who will succeed Rep. Fred Upton (R-MI), will take over the committee after successfully leading the House GOP's campaign arm and defending the party's majority status in 2014 and last month.

The committee's Health Subcommittee also will have a new leader next year after the retirement of Rep. Joe Pitts (R-PA). Rep. Michael Burgess (R-TX), an OB/GYN doctor for nearly 30 years, is likely to lead the subcommittee beginning in January.

Dems Vow to Fight GOP's "War on Seniors"

After President-elect Donald Trump nominated Rep. Tom Price (R-GA) to be HHS secretary, incoming Senate Democratic Leader Chuck Schumer (D-NY) accused Republicans of "plotting a war on seniors" by repealing the Affordable Care Act and backing Medicare changes. Schumer is aiming to rally Democrats to fight the GOP's healthcare agenda, especially the 10 Senate Democrats who are seeking re-election in 2018 in states Trump won last month. Although he lacks the votes to stop Republicans, Schumer is hoping to build public pressure among seniors to force the GOP to back off potential Medicare and ACA changes.

House Ways and Means Committee Chairman Kevin Brady (R-TX) said last week that Republicans won't push a Medicare overhaul early next year. Instead, he identified ACA transition issues as key GOP priorities early in 2017. Brady did say his committee early next year would push reform legislation focusing on post-acute care, including nursing homes, home health care agencies and rehabilitation facilities.

Price's Senate confirmation battle will begin next month. Already, Sen. Joe Donnelly (D-IN) – one of 10 Democrats seeking re-election in 2018 in states Trump won – said he would vote against Price because of his views on Medicare.

GOP Wants to Keep NIH's Collins

Leading House and Senate Republicans last week urged President-elect Donald Trump to carry over NIH Director Francis Collins into the new administration. House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Senate HELP Committee Chairman Lamar Alexander (R-TN) organized the letter to Trump supporting Collins' continued service. Both committees have legislative jurisdiction over NIH. Also joining the effort were Rep. Tom Cole (R-OK) and Sen. Roy Blunt (R-MO), both of whom chair appropriations subcommittees that fund NIH's budget.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions